ArticleBMC cancer2026
Development of a clinically applicable prediction tool for lymph node metastasis in papillary thyroid carcinoma using lasso-logistic regression.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aims to analyze clinical and laboratory data from patients to identify indicators associated with lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC). Furthermore, we aim to develop a nomogram and a web-based calculator for predicting the risk of LNM.
methodsWe conducted a retrospective analysis of 1,134 patients who underwent PTC resection between January 2018 and July 2023. The enrolled patients were randomly divided into a modeling set and a validation set in a 7:3 ratio. Lasso-logistic regression was employed to identify independent predictors of LNM in PTC. The dose-response relationship between independent influencing factors and the risk of PTC occurrence was assessed using restricted cubic spline (RCS). Finally, we evaluated the diagnostic value and clinical net benefit of each indicator using receiver operating characteristic (ROC) curves and decision curve analysis (DCA).
resultsLasso-logistic regression analysis revealed that ultrasound TI-RADS classification, nodule diameter, nodule number, gender, age, APOB, and CEA are independent predictors of LNM in patients with PTC. RCS analysis indicates that nodule diameter, age, CEA, and APOB levels exhibit both linear or nonlinear relationships with the risk of LNM in PTC patients. A nomogram and a web-based calculator were developed to predict the risk of LNM in PTC based on these characteristic variables. The full model's area under the receiver operating characteristic (AUROC) curve is 0.753 (95% CI: 0.716-0.790), with a mean cross-validation AUROC of 0.738 (95% CI: 0.710-0.768) and a pooled cross-validation AUROC of 0.734 (95% CI: 0.696-0.772). The AUROC value for the validation set is 0.733 (95% CI: 0.682-0.779), the prediction model demonstrates moderate discriminative ability. Calibration assessment using calibration plots, slope, intercept, and the Hosmer–Lemeshow test indicated acceptable agreement between predicted and observed risks. DCA demonstrated higher net benefit across clinically relevant thresholds, and the clinical impact curve (CIC) showed good agreement between predicted high-risk patients and observed events. Furthermore, the model has been transformed into a freely accessible web-based calculator (https://ley120.shinyapps.io/Lymph_Node_Metastasis_in_PTC/).
conclusionTI-RADS classification, Nodule diameter, Nodule number, Gender, Age, APOB, and CEA have moderate diagnostic value in evaluating lymph node metastasis of PTC. This study developed a nomogram with acceptable discrimination for predicting LNM risk in PTC, which may assist clinicians in risk stratification when used alongside other clinical assessments. This model serves as a supplementary tool for risk estimation rather than a definitive diagnostic standard.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.